You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Popup

Request a contact

Live chat

Introducing Cervarix

Cervarix is a vaccine for use from the age of 9 years for the prevention of pre-malignant genital lesions and cervical cancer causally related to certain oncogenic human papilloma virus (HPV) types.1

Cervical Cancer

Efficacy

Cervarix efficacy has been studied in various studies of which the pivotal trial was PATRICIA. Data on prevention of CIN3+, the last stage before invasive cancer, are considered to be the most robust indicator of cervical cancer protection. 2

Read more on PATRICIA CIN3+ data

Safety

The most common adverse reaction observed after vaccine administration was injection-site pain which occurred after 78% of all doses. The majority of these reactions were of mild-to-moderate severity and were not long lasting. 1

Full safety information

Papilloma_Virus

Cervical Cancer

Cervical cancer is the fourth-most common cancer in women 3

It is a malignant tumour that occurs in the transformation zone of the cervix uteri.4

Read more

References:

  1. Cervarix IPI Version number: GDS024/ IPI019 / Date of issue: 02/Mar/15 2015 GSK group of companies
  2. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89–99.
  3. GLOBOCAN. Cervical Cancer Incidence and Mortality Worldwide in 2012: Cancer Fact Sheet. Available at: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp. Last accessed February 2017.
  4. American Cancer Society - Cervical cancer? Available at: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer. Last accessed February 2017.

Cervarix is a registered trademark of GlaxoSmithKline group of companies.